Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker Phase II Study Of Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer
2024-511292-15-00Phase 2Completed
- Sponsor
- Spanish Group of Neuroendocrine Tumors
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib in well-differentiated thyroid cancer (WDTC), sponsored by Spanish Group of Neuroendocrine Tumors. Primary endpoint: cfCHIP-seq profiling on isolated chromatin nucleosomes. Started May 2023; status: completed.
02
Drugs
cabozantinib
03
Conditions
well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on 2024-511292-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511292-15-00.